Emicizumab in Acquired Hemophilia A
Condition: Adult Patients (>= 18 Years) Diagnosed With Acquired Hemophilia A (AHA) Based on a Reduced FVIII Activity and a Positive Nijmegen Bethesda Inhibitor Titer Intervention: Drug: Emicizumab Injection Sponsors: GWT-TUD GmbH; Hoffmann-La Roche; Hannover Medical School Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials